I am a
Home I AM A Search Login

Papers of the Week

Papers: 19 Jun 2021 - 25 Jun 2021

Human Studies, Pharmacology/Drug Development


2021 Jun 21


Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study.


Takeshima T, Sakai F, Hirata K, Imai N, Matsumori Y, Yoshida R, Peng C, Cheng S, Mikol DD
Headache. 2021 Jun 21.
PMID: 34153117.


Erenumab is a human anti-calcitonin gene-related peptide receptor monoclonal antibody approved for migraine prevention. Global studies have demonstrated its efficacy in chronic and episodic migraine (EM). Here we report the outcomes from a Phase 3 study of erenumab in Japanese patients with chronic migraine (CM) or EM.